Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ZLAB | US
0.75
2.93%
Healthcare
Biotechnology
30/06/2024
04/10/2024
26.36
25.01
26.42
25.01
Zai Lab Limited develops and commercializes therapies to treat oncology autoimmune disorders infectious diseases and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma diffuse large B-cell lymphoma and other B-celllymphomas; Repotrectinib a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC colorectal cancer pancreatic cancer and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib an orally bioavailable multi-targeted kinase inhibitor; ZL-2313 an investigational oral EGFR inhibitor; ZL-1211 a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102 a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai China.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
76.5%1 month
59.1%3 months
51.0%6 months
63.5%-
-
3.34
0.12
0.08
-2.35
5.46
-
-343.59M
2.63B
2.63B
-
-75.68
-
45.90
-36.46
8.88
6.26
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
6.25
Range1M
7.51
Range3M
10.41
Rel. volume
1.10
Price X volume
18.57M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.35 | 0.76 | Cheaper |
Ent. to Revenue | 5.46 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.34 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 50.97 | 74.67 | Lower Risk |
Debt to Equity | 0.12 | -1.82 | Expensive |
Debt to Assets | 0.08 | 0.26 | Cheaper |
Market Cap | 2.63B | 3.73B | Emerging |